Summarized by Masters of Longevity from Longevity Technology.
This article previews a pharma regulatory update describing agreed trial design elements for a forthcoming pivotal study in dementia with Lewy bodies, useful for investors and clinicians.
Key Takeaways
- The trial will use NPI-2 to measure hallucinations and delusions in patients.
- Daily functioning will be measured using the ADCS-ADL scale as a secondary endpoint.
- Cognition Therapeutics and the FDA agreed on core design elements for the Phase 3 trial.
